← feed

Is NCT03245385 results overdue?

Yes — results are overdue. Primary completion was 2018-02-05; the FDAAA-801 reporting deadline (2019-02-05) passed 2739 days ago and no results are posted on ClinicalTrials.gov.

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT IDNCT03245385 ↗
SponsorSun Pharmaceutical Industries Limited (INDUSTRY)
PhasePHASE2
StatusTERMINATED
Primary completion2018-02-05 (ACTUAL)
Reporting deadline2019-02-05 (completion + 365d)
Days overdue2739
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 ee5325d488f40b6b… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03245385. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →